A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05070247. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05070247
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Takeda
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- Dexamethasone Drug
- Pembrolizumab Drug
- TAK-500 Drug
- Tocilizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 13, 2022
- Primary completion
- Jan 5, 2025
- Completion
- Jan 5, 2025
- Last update posted
- Jan 21, 2026
2022 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Univeristy of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| University of California San Diego | La Jolla | California | 92093 | — |
| University of Colorado - Anschutz Medical Campus - PPDS | Aurora | Colorado | 80045 | — |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Northwestern | Chicago | Illinois | 60611 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| New York University | New York | New York | 10016-4744 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Sarah Cannon Cancer Institute | Nashville | Tennessee | 37203 | — |
| START South Texas Accelerated Research Therapeutics | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05070247, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 21, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05070247 live on ClinicalTrials.gov.